 |
Altea Therapeutics has developed an advanced drug delivery system that allows a wide variety of drugs and vaccines across the skin. This breakthrough should improve the efficacy, safety and compliance of drugs and vaccines.
Co-investors: Domain Associates, Venrock Associates, vSpring Capital
|
||
 |
Bidshift is an IT company focused on providing
flexible workforce management solutions to
healthcare facilities. The company's lead offering is a software system that enables hospitals to create and manage an internal registry for nurses and other clinical staff, providing significant ROI for hospitals and flexibility and increased income for the hospital staff.
Co-investors: Himalaya Capital, Kaiser Ventures, RK Ventures
|
 |
Cardiocore Lab, Inc. advances the quality and speed of clinical trials by providing the world’s finest cardiac testing services. Centralized services include ECG analysis, Holter monitoring, protocol design and statistical analysis.
Co-investors: Caxton Health
|
 |
CardioMEMS, Inc. is a medical device company that develops wireless medical pressure sensors. The technology platform is initially designed to improve the management of severe cardiovascular diseases such as heart failure and aneurysms. Co-investors: Boston Millenia, Arcapita Ventures, Foundation Medical, Easton Capital, Medtronic
|
||
 |
Ception
Therapeutics, Inc. is an emerging
biopharmaceutical company discovering and
developing novel biologic and small molecule
agents to address unmet medical needs. The
company has late stage biologic anti-inflammatory
programs, a small molecule anti-TNF program and
several other discovery programs.
Co-investors: Essex Woodlands, Investor Growth Capital, MDS, New Science Ventures, Third Point
|
||
 |
Conor Medsystems is a medical device company that develops stents and other medical devices as delivery platforms for controlled local delivery of a wide variety of therapeutic agents. Its proprietary technologies enable the delivery of multiple drugs or biotech compounds to various sites in the body.
Co-investors: Easton Capital, Highland Capital, Radius Ventures NASD: CONR Acquired by Johnson & Johnson
|
||
 |
MAKO Surgical is a medical device
company that is developing advanced technologies and
procedures for the rapidly emerging orthopedic
minimally invasive total joint market.
Co-investors: Exxel Group, Ivy Capital, MDS Capital, Tudor Investments NASD: MAKO
|
||
 |
Redpoint
Bio is a biotechnology company that has made breakthroughs in the science of taste: the elimination of the perception of bitterness and the enhancement of the sweetness of natural sugar. These breakthroughs can potentially be used extensively in the pharmaceutical and food and beverage industries. The product line will consist of natural compounds that will have their desired effects when mixed with the target products.
Co-investors: Cargill Ventures, NJTC Ventures, SR One OTCBB: RPBC
|
||
 |
Synta is an emerging, innovative pharmaceutical company focused on developing novel drugs for the treatment of cancer and immune disorders. The Company has a diverse pipeline of blockbuster-potential drug candidates, diverse chemical library and strong financial backing.
Co-investors: Caxton Group, Duquesne Capital, Gollust Management NASD: SNTA
|
||
 |
The Protective Group is a leading provider of technologically advanced safety products to military forces, law enforcement agencies and fire departments throughout the United States and internationally.
Co-investors: Exxel Group
|
||
 |
TherOx
developed its SuperSaturated Oxygen Therapy to treat
ischemic tissues and conditions.
Using the TherOx technology, hyperbaric levels of
oxygen can be delivered to the heart to salvage
tissue affected by acute myocardial infarction. This is the first of many
applications for TherOx’s technology platform.
Co-investors: Kleiner Perkins, DAG Ventures, Integral Capital, New Science Ventures, Wasatch Ventures
|
||
 |
TransMolecular is a biotechnology company committed to discovering, developing and commercializing novel and proprietary drugs to diagnose and treat cancer and pain. TransMolecular is developing a targeted approach to treating cancer using synthetic versions of peptides isolated from natural products. The company's lead compound, targeting a deadly form of brain cancer, is in
clinical trials.
Co-investors: Easton Capital, MDS Capital, Tullis Dickerson, TVM Capital |